Lomefloxacin

Lomefloxacin (SC47111A) is an orally active difluoroquinolone antibiotic. Lomefloxacin prevents DNA supercoiling and replication by inhibiting bacterial topoisomerase II. Lomefloxacin induces ROS production and Apoptosis. Lomefloxacin has broad-spectrum bactericidal activity against Gram-positive and Gram-negative bacteria. Lomefloxacin has anticancer effects against melanoma. Lomefloxacin can be used in the study of systemic bacterial infections (such as Salmonella typhimurium infections), skin and melanoma ^{[1][2][3][4][5][6]}. IC50 & Target:MIC₉₀: 0.12 mg/L (Haemophilus influenzae), 0.25 mg/L (Moraxella catarrhalis), 0.06 mg/L (Legionella pneumophila)^[1] In Vitro:Lomefloxacin (1/4 to 2×MIC concentrations) rapidly reduces viable cell counts of Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, with no regrowth observed in all strains except P. aeruginosa^[1].
Lomefloxacin exhibits MIC values ranging from 0.06-4 μg/mL in susceptibility determination experiments with strains such as Escherichia coli and Staphylococcus aureus^[2].
Lomefloxacin (0.1-1.0 mM; 24-72 h) decreases viability of COLO829 cells and induces ROS production in COLO829 cells^[3].
Lomefloxacin (50-100 μM) induces apoptosis in keratinocyte^[4].
In Vivo:Lomefloxacin (ED₅₀: 1.45-32.2 mg/kg; p.o.; immediately after infection) significantly reduces mortality in mice with intraperitoneal infection models, with ED₅₀ values lower than those of Ofloxacin and Norfloxacin^[1].
Lomefloxacin (-80 mg/kg; orogastric administration) reduces mortality, significantly decreases splenic bacterial counts, and inhibits inflammatory response in mice infected with Salmonella typhimurium^[5].
Lomefloxacin (16-32 mg/kg; i.p.; 5 days) only at the highest dose slightly reduces the number of implants and live fetuses in the third week of mating in mice, without significant dominant lethal mutation induction^[6].